| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 19 oct 2026Próximo | Q3 2026 | Antes de apertura | 2,88 | 3,07 B |
25 ago 2026
While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m. Eastern Time.
Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform.
24 ago 2026
Digi Power X Inc (NASDAQ:DGXX, FRA:1NQ0, NEO:DGX) insiders bought shares in back-to-back open-market purchases this week, according to regulatory filings. President and director Amar Alec purchased 10,000 subordinate voting shares on August 20 at a weighted average price of $3.86 per share,...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m. Eastern Time.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patientsQuest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10%
21 ago 2026
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
20 ago 2026
Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...
Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...
18 ago 2026
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BOSTON, August 18, 2026--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE: DGX).
Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.
14 ago 2026
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
12 ago 2026
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.
